Browse files

Dataset

CM214 - Biomarker Analysis From the Phase 3 CheckMate 214 Trial of Nivolumab Plus Ipilimumab (N+I) or Sunitinib (S) in Advanced Renal Cell Carcinoma (aRCC)

Dataset ID	Technology	Samples
EGAD00001007938	Illumina HiSeq 2500,Illumina NovaSeq 6000	213

Dataset Description

CM214 - Biomarker Analysis From the Phase 3 CheckMate 214 Trial of Nivolumab Plus Ipilimumab (N+I) or Sunitinib (S) in Advanced Renal Cell Carcinoma (aRCC)

Data Use Conditions

HMB DS

See further information on Data Use Conditions

Label	Code	Version	Modifier
health or medical or biomedical research	DUO:0000006	2021-02-23
disease specific research	DUO:0000007	2021-02-23	MONDO:0013209

Who controls access to this dataset

For each dataset that requires controlled access, there is a corresponding Data Access Committee (DAC) who determine access permissions. Access to actual data files is not managed by the EGA. If you need to request access to this data set, please contact:

BMS Data Sharing Request Committee
Contact person: CTT Group
Email: ctt [dot] group [at] bms [dot] com
More details: EGAC00001002243

Downloads

You don't have access to the download section.

This dataset is featured in 1 study

Studies are experimental investigations of a particular phenomenon. e.g. case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients. Click on one of the Study IDs below to find out more.

Study ID	Study Title	Study Type
EGAS00001005501	CM214 - Biomarker Analysis From the Phase 3 CheckMate 214 Trial of Nivolumab Plus Ipilimumab (N+I) or Sunitinib (S) in Advanced Renal Cell Carcinoma (aRCC)	Other

EGA Beacon